All In Biotech

NDA 204671 · Gilead Sciences INC

Sovaldi

Sofosbuvir · Oral · Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Dec 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Dec 6, 2013

Approved uses

3

Original approval plus efficacy supplements

Registered trials

343

110 Phase 3, 6 recruiting

FAERS reports

19,622

14,219 serious, 1,800 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with SOVALDI. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ] . WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B...

What it is approved for

From the label in effect Dec 26, 2024.

SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of: Adult patients with genotype 1, 2, 3 or 4 chronic HCV infection without cirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment regimen. ( 1 ) Pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis in combination with ribavirin. ( 1 ) Adult Patients: SOVALDI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen [see Dosage and Administration (2.2) , and Clinical Studies (14) ]: genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis for use in combination with pegylated interferon and ribavirin genotype 2 or 3 infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. Pediatric Patients: SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin [see Dosage and Administration (2.3) and Clinical Studies (14.5) ] .

Mechanism: Sofosbuvir is a direct-acting antiviral agent against the hepatitis C virus [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • SOVALDI · SOFOSBUVIR 400MG · TABLET, ORAL · Prescription · TE AB
  • SOVALDI · SOFOSBUVIR 200MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sofosbuvir" as an intervention, any sponsor and status, largest first.

All 343 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,317
  • drug ineffective1,931
  • hepatitis c1,736
  • headache1,646
  • nausea1,398
  • off label use1,389
  • anaemia1,190
  • insomnia1,065
  • hepatocellular carcinoma911
  • treatment failure837
  • dyspnoea789
  • asthenia781

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20111
20122
201339
20143,690
20155,519
20164,033
20172,503
20181,579
20191,127
2020353
2021198
2022195
2023141
2024139
202579
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sovaldi (Sofosbuvir)

2024 spending

$2.2M

Beneficiaries

23

81 claims

Per beneficiary

$94,774

$961.11 per unit

View as table
YearSpending
2020$4,150,187
2021$2,474,910
2022$2,189,001
2023$1,955,322
2024$2,179,806

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 454 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.